Get the Stockscreener App
141.71
0.86%
1.21
After Hours:
141.98
0.27
+0.19%
Biogen Inc Stock (BIIB) Latest News
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire Inc.
Eisai/Biogen’s Alzheimer’s Drug Finally Closing In On EU Approval - Scrip
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion - BioSpace
Biogen's Alzheimer's Treatment Lecanemab Denied Approval in Australia -March 03, 2025 at 07:29 am EST - Marketscreener.com
QALSODY™ (tofersen injection) Receives Conditional Marketing Authorization from Health Canada as the First ALS Treatment Targeting a Genetic Cause - Yahoo Canada Finance
Fisher Asset Management LLC Grows Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
National Pension Service Has $38.24 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
2,819 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Advisor OS LLC - MarketBeat
Biogen Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your RightsBIIB - ACCESS Newswire
3 Reasons BIIB is Risky and 1 Stock to Buy Instead - Yahoo Finance
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia - Biogen | Investor Relations
Bank of New York Mellon Corp Has $149.07 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Impax Asset Management Group plc Reduces Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Private Advisor Group LLC Cuts Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Stake Boosted by Y Intercept Hong Kong Ltd - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 1,900 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Leqembi, after delay, gets back on track toward EU approval - BioPharma Dive
EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug - Reuters
Eisai and Biogen’s Alzheimer’s drug lecanemab nears EU approval - Investing.com
Biogen, Eisai Alzheimer’s drug set for EU nod (BIIB:NASDAQ) - Seeking Alpha
Biogen, Eisai Say EMA Panel Reaffirms Positive Opinion on Lecanemab -February 28, 2025 at 08:57 am EST - Marketscreener.com
Eisai and Biogen’s Alzheimer’s drug lecanemab nears EU approval By Investing.com - Investing.com South Africa
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease – Company AnnouncementFT.com - Financial Times
EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes - Marketscreener.com
EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug -February 28, 2025 at 07:48 am EST - Marketscreener.com
EMA's CHMP Says Opinion Recommending Marketing Authorisation For Leqembi Not Need To Be Updated - Marketscreener.com
Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Truist Financial Corp - MarketBeat
Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Biogen to Participate in the Leerink Global Healthcare Conference 2025 - Biogen | Investor Relations
April 11th Options Now Available For Biogen (BIIB) - Nasdaq
Biogen Inc. (NASDAQ:BIIB) Shares Bought by New York State Common Retirement Fund - MarketBeat
Red Biotechnology Market Growth and Future Scope 2025-2032 | Amgen Inc., Gilead Sciences, Inc., Biogen - openPR
Principal Financial Group Inc. Decreases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your RightsBIIB - ACCESS Newswire
Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Handelsbanken Fonder AB Buys 13,433 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts - Insider Monkey
Allianz Asset Management GmbH Raises Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen to Participate in the TD Cowen 45th Annual Health Care Conference - Biogen | Investor Relations
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects - AOL
Biogen Stock Outlook: Is Wall Street Bullish or Bearish? - Nasdaq
Biogen Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart
Meitav Investment House Ltd. Increases Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Gene Therapy Market Top Companies Study- Novartis Ag, Biogen - openPR
The week in pharma: action, reaction and insight – week to February 21 - The Pharma Letter
ING Groep NV Has $3.39 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
3.76%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):